Cite
Venous thromboembolism in cancer: what is the optimal treatment? Strong evidence favors use of low molecular weight heparin to treat and prevent VTE in patients with cancer, but many clinicians have yet to modify their clinical practice
MLA
Posner, Jana, and Denise Rizzolo. “Venous Thromboembolism in Cancer: What Is the Optimal Treatment? Strong Evidence Favors Use of Low Molecular Weight Heparin to Treat and Prevent VTE in Patients with Cancer, but Many Clinicians Have yet to Modify Their Clinical Practice.” JAAPA-Journal of the American Academy of Physicians Assistants, vol. 24, no. 8, Aug. 2011, p. 44. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.299990586&authtype=sso&custid=ns315887.
APA
Posner, J., & Rizzolo, D. (2011, August 1). Venous thromboembolism in cancer: what is the optimal treatment? Strong evidence favors use of low molecular weight heparin to treat and prevent VTE in patients with cancer, but many clinicians have yet to modify their clinical practice. JAAPA-Journal of the American Academy of Physicians Assistants, 24(8), 44.
Chicago
Posner, Jana, and Denise Rizzolo. 2011. “Venous Thromboembolism in Cancer: What Is the Optimal Treatment? Strong Evidence Favors Use of Low Molecular Weight Heparin to Treat and Prevent VTE in Patients with Cancer, but Many Clinicians Have yet to Modify Their Clinical Practice.” JAAPA-Journal of the American Academy of Physicians Assistants, August 1. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.299990586&authtype=sso&custid=ns315887.